PRG 017 USB PIC PROGRAMMER SOFTWARE PLUS

100%+ historical Dollar Based margin вЂAnalytics ApplicationвЂ™ or Q4 2020 Net Retention layer of our offering.

Estimated to close in Q3 TAM, primarily at the high.

150+ hospital and health the transaction is closed on ARR targets system customers, presenting cross-sell opportunity.

20%+ long term revenue growth target Additional details will be incorporated into guidance once - Potential earnout based.

Timing of close and purchase - $70M in cash year recurring revenue with accounting impact of deferred 20%+ annual historical revenue write-down will impact - $50M in HCAT common revenue growth 20 GAAP revenue and EBITDA contribution.

Historical and projected technology revenue operating leverage.

Transaction Overview & Vitalware Financial Profile Transaction Financial Profile Overview

Vitalware currently integrates billing, claims, pharmacy, and supply data, leveraging its robust pre- built rules-based content.

Meaningful upsell opportunity with newer product suites in Revenue Integrity and Price Rationale Transparency.

Flagship offering is a best-in-KLAS Chargemaster workflow solution that solves a complex regulatory and billing function Strategic - Taking meaningful market share from competitors.

DOS will further enhance analytics insights by integrating charge and revenue data with claims, cost, and quality data.

Strategic anchor technology in the revenue space to expand our CFO value proposition.

Also offers newer product suites in: - Revenue Integrity to capture lost revenue Overview - Price Transparency to support compliance with expanding pricing transparency regulation.

Flagship offering is a best-in-KLAS Chargemaster workflow solution.

Offers a revenue workflow optimization and analytics SaaS technology solution.

Vitalware Overview & Strategic Rationale for Acquisition The parties expect the Acquisition, which is subject to customary closing conditions, will close in the third or fourth quarter of 2020. The actual number of shares that will be issued under the earnout, if any, will depend on the extent of fulfillment of the earnout performance targets at the time of calculation of the earnout. For purposes of the earnout, the Common Stock will be valued based on the average trading price of the Common Stock on the Nasdaq Global Select Market for the 35 consecutive trading day period ending March 31, 2021. Health Catalyst also agreed pursuant to an earnout provision to issue additional shares of Common Stock if certain earnout performance targets are met during an earnout period ending on March 31, 2021. As a portion of the consideration for the Acquisition, Health Catalyst has agreed to issue 1,487,210 shares of Health CatalystвЂ™s common stock, $0.001 par value ('Common Stock'), valued at the closing reference price of $33.62, which is equal to the average trading price of the Common Stock on the Nasdaq Global Select Market for the 35 consecutive trading day period ended August 7, 2020, to the equityholders of Vitalware upon consummation of the transactions contemplated by the acquisition agreement, subject to certain closing conditions.

PRG 017 USB PIC PROGRAMMER SOFTWARE PLUS

(вЂњHealth CatalystвЂќ) entered into an acquisition agreement to acquire all of the equity interests in Vitalware, LLC, a Delaware limited liability company (вЂњVitalwareвЂќ), for an aggregate purchase price of approximately $120 million, plus a potential earnout described below of up to $30 million (the вЂњAcquisitionвЂќ). On August 11, 2020, Health Catalyst, Inc.

Prg-017 usb pic programmer software